Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects

Bersiporocin, a novel first‐in‐class prolyl‐tRNA synthetase (PRS) inhibitor currently under clinical development, was shown to exert an antifibrotic effect through the downregulation of collagen synthesis in various pulmonary fibrosis models. The aim of this first‐in‐human, randomized, double‐blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Min Young, Bae, Sungyeun, Heo, Jung A, Park, Mihee, Kim, YuKyung, Han, Jumi, Jang, In‐Jin, Yu, Kyung‐Sang, Oh, Jaeseong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339703/
https://www.ncbi.nlm.nih.gov/pubmed/37095713
http://dx.doi.org/10.1111/cts.13518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339703/
https://www.ncbi.nlm.nih.gov/pubmed/37095713
http://dx.doi.org/10.1111/cts.13518

Ejemplares similares